Member Info for rivaldo

I'm happy to hold for upside which should come to fruition (pun intended!) this year. Here's Beaufort Securities' view - they say Buy with a 23p target price. Note the P/E's of just 6.8 falling to 5 for this this year and next year: "Our view: DekelOil delivered strong results for the FY2016 with record production and over ten-fold increase in post-tax profit, despite the fall in average CPO prices and FFB yield. Looking ahead, in FY2017, the Group said market prices for both CPO and PKO has improved in the H1, therefore is on track to deliver further increases in sales. This year will also expect materially lower financing costs as the Group will see the first full year benefit of the revised debt term. Altogether, this enables the Group to commence maiden dividend in FY2017 which the management said it expect to pay a total of £500,000, implying c.0.17p per share. For the medium-term, as the company-owned estates reaching maturity, as well as improvement in farming practices of the smallholders supported by the World Bank scheme, these are expected to result in increased volumes of feedstock. Together with this, the Group’s investment in improved extraction rate and increased CPO storage capacity (to 8,000 tonnes) will further support the future sales growth. DekelOil has also invested in back-up facilities during the year which is now in place to minimise the operational risk. Beaufort believe DekelOil’s current share price yet to truly appreciate the potential upsides from ramp up of its CPO production from now wholly-owned Ayenouan, where c.30% of the operational capacity at the CPO extraction mill is yet utilised (maximum capacity 70,000 tonnes per annum). Moreover, the management confirmed on 10 May 2017 that it is currently in discussion with Norpalm Ghana Limited (subsidiary of Norpalm AS) and certain Norpalm AS shareholders in relation to the potential acquisition of all or the majority of the shares in Norpalm by DekelOil to build out its operations in neighbouring Ghana. Norpalm is an owner and operator of c.4,000 hectares of mature palm plantations and operates a 30 tn/hr mill which also purchases FFB from local producers. Norpalm sells 15,000 tonnes of crude palm oil sold into the domestic Ghanaian market, and also operates a PKO press which produces c.2,000 tn of PKO in the Ghanaian market. Such discussions are still ongoing and therefore there can be no guarantee that it will proceed.....The Group will make further announcements in due course. Overall, given the Group has strengthened balance sheet and revenue profile while set to transform itself into a list of dividend paying company with a progressive policy in place, upsides for the shareholders are increasing on this obviously undervalued investment. The Shares are currently valued at FY2017E and FY2018E P/E multiple of 6.8x and 5.0x, along with dividend yield of 1.3% for both, respectively. Beaufort retains its Buy rating on the Sh

with buying at 232p....yet still only on a current year P/E of 8.8 based on consensus 26.1p EPS.

N+1 Singer are forecasting (conservatively) 12.5p EPS this year, but rising 20% to 15p EPS next year. Even on a pretty prudent P/E of 13 it's therefore possible to see at least a 200p share price in say 9 months' time as CAR ends this year and moves towards the 2018/19 year. Hawker, it's a poor day for the markets today - it's an achievement for CAR's share price to even be up today! Let's wait for the inevitable Buy tips to come through and for institutional buyers to assess their positions - I suspect in 3-4 weeks' time in reasonable markets CAR may have pushed a decent amount upwards.

Peel Hunt have increased their price target to 200p (from 190p): Https://sportsperspectives.com/2017/06/06/carclo-plc-car-price-target-increased-to-gbx-200-by-analysts-at-peel-hunt.html

Excellent results - 19.2p EPS is ahead of consensus expectations, as is the 8.5p dividend: Http://www.investegate.co.uk/acal-plc--acl-/rns/final-results/201706060700031991H/ - order books are up strongly - acquisitions performing well, with more acquisitions likely - good cash flows - efficiency programme to benefit this year - D&M now up to 52% of sales - this Q1 looking great The outlook says it all: ""As expected, the second half of the year saw accelerating levels of organic growth in sales and orders, and excellent cash flow. This strong momentum has continued into the new financial year which we entered with an order book 22% higher at CER than the prior year, and which is driving further good growth in this first quarter as the order book converts into sales. Our efficiency plan has been implemented, delivering £4m in sustainable annual savings and at a better than anticipated cost of implementation. Variohm Group, acquired in January 2017, is performing very well. Cross-selling activities are underway with a number of exciting opportunities identified and our first design win has been achieved, ahead of plan. This is the seventh consecutive year in which the dividend has increased - an increase of 67% in total, reflecting the transformation of the Group over this period. In the last four years alone, revenues have almost doubled and underlying operating profits quadrupled. We plan to continue this strong rate of progress through further organic growth and high quality acquisitions over the next five years."

Excellent results - 12.1p EPS is well ahead of consensus 11.45p EPS expectations. With consensus 13p EPS for this year, the P/E is now just 10.8: Http://www.investegate.co.uk/carclo-plc--car-/rns/final-results/201706060700031970H/ - underlying profits up 25% - EPS up 20% - both CTP and Wipac going gangbusters - and this year looking great with a "Strong order book and momentum into the new financial year" The narrative details the big opportunities and expansion going on worldwide - all customer and order-led. The outlook sums it up: "The Group has yet again delivered a strong trading performance during the year, and made excellent progress in implementing its stated strategic objectives. The two acquisitions made during the year are well aligned to our strategy and we have been successful in rapidly integrating both companies into the Group. Having exited the year with record order intake and pipeline within CTP and with the early delivery of our objective for Wipac of securing a second mid-volume lighting programme, we remain on course to deliver strong improvements in returns over the coming years to our shareholders." The pension deficit has reduced hugely since the interims, and the company note that 2018/19 may see the return of dividends. The share price is extremely cheap imo.

Finncap have increased their target price to 350p today (from 325p). Looks like a few nervous nellies taking profits and concentrating on the historic hiatus in the USA rather than the overall context as I posted above - volumes are small and the MMs are taking advantage. It wouldn't surprise me to see a decent bounce.

RNS - Thomas Charlton has gone above 3% with 242,500 shares: Http://www.investegate.co.uk/chamberlin-plc--cmh-/rns/holding-s--in-company/201706050700040846H/ It's worth noting who exactly he is.... Https://www.bloomberg.com/research/stocks/people/person.asp?personId=9011989&privcapId=877542 "Mr Thomas William George Charlton, also known as Tom, MA served as Managing Director of Merrill Lynch Investment Managers from 1998 to August 2002. Mr. Charlton has in-depth investment knowledge together with broad experience and interest in the smaller companies sector. etc"

- trading in line with market expectations for the year to date - and a whopping 10p+ special dividend for holders on 28th July And this achieved despite weather-related delays in the USA and slow growth in China! Strong European trading and elsewhere has driven the growth. With the USA and China recovering, prospects remain good, reflected in the special dividend, the additional HQ expansion and the growing cash pile.

Http://www.syngene.com/gbox-chemi-gel-imaging-system-helps-in-neurodegenerative-research/ "Friday 2nd June 2017 Leading German University opts for second Syngene imaging system Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, today announced its G:BOX Chemi XX6 multi-application imager is being utilised by scientists at a top University in Germany to speed up analysis of genes and proteins associated with neurodegenerative conditions. Researchers at the German University are using a G:BOX Chemi XX6 multi-application imager to rapidly detect genotypic changes on fluorescent DNA gels and accurately analyse proteins expressed in human cell lines and animal models of neurodegenerative diseases. To detect changes in protein expression, the scientists are utilising ECL-based chemiluminescent Western blots. This data is providing information which could help develop safer, more effective immunotherapies to treat incurable neurodegenerative conditions. The Laboratory Manager at the German University stated: “We have had an older Syngene gel doc system in our lab for many years, which we use for visualising DNA on our genotyping gels. We are very happy with its performance but this system cannot analyse chemiluminescent Western blots. This meant we were spending many hours developing X-ray film of our Westerns and it was difficult, as well as time consuming trying to quantify protein amounts.” The Laboratory Manager continued: “We upgraded to the newer G:BOX Chemi XX6 in 2016 because we like how quick and easy the Syngene imaging software is to use. The system is now being used daily by 10 researchers and we’re analysing our Western blot results much faster than when we were using X-ray film. The other benefits are that we have confidence in the protein quantification results we’re obtaining and we can store images which we can use directly in publications so we’re very happy with our G:BOX Chemi XX6 system.” To find out about the exciting applications a G:BOX Chemi XX6 imager can perform, scientists can click this link: www.syngene.com/g-box-chemi-xx6/ “We’re proud to hear that this major German University has installed a second Syngene imaging system to accelerate their research in neurodegenerative diseases,” states Dr Martin Biggs, Sales Manager at Syngene. “Their choice of a G:BOX Chemi XX6 for use by so many different researchers demonstrates how robust and easy to use this technology is for producing accurate protein expression and genotyping results.”

Good to see the head of private client investment management at Thomas Miller Investments tipping NCC: Http://www.whatinvestment.co.uk/uk-small-cap-tech-stock-thats-rare-opportunity-2553693/ "1 Jun 2017 Andrew Herberts, head of private client investment management at Thomas Miller Investments, has revealed the UK small cap share that offers an opportunity for investors to access fast growing sectors of the technology market. The stock in question is NCC Group. He commented, ‘NCC Group is a rare opportunity to get exposure to online and software security through its Assurance and Escrow Divisions. Through recent acquisition, it now offers a service proposition combining consultancy, managed services and products. With cyber-security becoming a higher and higher management priority, Assurance should see significant top line growth. M&A has been NCC’s Achilles heel. It grew quickly organically and then began to round out its proposition through a slew of acquisitions. These purchases and the attempts to integrate them showed weaknesses in its management control systems and processes which led to weak updates in November and February and a total stock price fall of over 70 per cent. While it has rallied 50 per cent since, it is still less than half its high of 367p achieved in September 2016 and trades on 20 (times) 2018 earnings estimates.’ NCC Group has a market cap of £472 million, and has a current dividend yield of 2.8 per cent. For the year to the end of May 2016, the company posted a profit of £9.4 million on a turnover of £209 million It is a curious feature of this company that despite turnover being more than double that of five years ago, the profit number has halved."

Here's Tempus' tip in the Times: Https://www.thetimes.co.uk/edition/business/a-pig-of-a-year-but-well-worth-a-poke-08kqrj6dw "Watkin Jones Watkin Jones’s recent decision to enter the build-to-rent sector was a natural one. The company specialises in building university accommodation and the two sectors have similar characteristics. Most students now expect university halls that more closely resemble a modern rental apartment complex than the stereotypical dingy student digs. The company has completed its first scheme in Leeds with 322 apartments managed by its Five Nine Living business, but its pipeline for future developments is also gathering momentum, with three sites secured in London, Belfast and Leicester. It continues to benefit from expanding demand for student beds, as universities focus on lecture halls, libraries and laboratories rather than accommodation. The group has sold seven student developments since October 1 and is fully forward sold for the financial year. For 2018, it has 3,400 beds due for delivery, more than half of which are forward sold. This makes for a solid investment case, especially after the 10 per cent increase in the interim dividend. Pre-tax profits grew by 27 per cent to £21.2 million, while its balance sheet is ungeared with net cash set to be £60 million by the end of the year. MY ADVICE Buy WHY Demand for student beds provides strong base"

yesterday, this extract in particular: Http://www.growthcompany.co.uk/renew-delivers-sound-performance-2556358/ "No worries Relatively new CEO Paul Scott told GCI he has no stand-out issues to worry about at the moment and our conversation underscored the impression of a company performing well. Net debt was £3.5 million at the half year but this is expected to move to a net cash position by the year end. The active M&A pipeline is said to be ongoing."

with buying at 282p and 283p. No-one else interested here yet then?! No doubt the share price will have to increase another 25% before others finally latch on.

from 185p today - and say Buy.

Regarding the chaos at BA, Air Partner have just released this statement noting that private aviation numbers have soared - in particular, note that Farnborough Airport was the "most popular" amongst their clients. It just so happens that GMAA's main base of operations is at Farnborough - perhaps this explains why the GMAA non-exec decided to buy those shares on Tuesday: Htp://www.airpartner.com/es/notas-de-prensa/air-partner-supports-clients-through-travel-chaos/ "Air Partner, the global aviation services group, has swung into action to support its clients through the chaos that impacted commercial flights during one of the busiest weekends of the UK holiday calendar, with people wishing to take advantage of the bank holiday and half term get away period. Julia Timms, Air Partner’s Group Marketing Director, commented: “Enquiries for Air Partner’s private jet services have been up 76% compared to the same bank holiday weekend last year.” “Colleagues have worked over the weekend to support new enquiries and our existing JetCard clients – to help get them to their destinations at the last minute.” “While private jets supply has held up - landing and take-off slots into popular and restricted destinations, such as Ibiza - have become hard to come by as the number of people turning to private jets increased.” “The most popular destination enquires have been for Barcelona, Lisbon, Nice, Palma and Faro - often for family holidays.” “Many families had planned to go abroad for the bank holiday or half term holiday, and traditionally there are very few last minute seats available at this time of year – so some people have been turning to private aviation as an alternative.” "One client and his wife were separated from their two young daughters and nanny, when their original flight from London to France was cancelled. Air Partner arranged a charter as quickly as possible to reunite the family." “However, we’ve also seen some clients booking ahead for business trips next week, as they’re expecting the chaos to linger for a few days. One FTSE 100 CEO was unable to get from Geneva to Heathrow today on a commercial service, so called on us to charter an aircraft to Farnborough airport so that he could attend critical meetings." “Clients flew out of the typical private airports – with Biggin Hill and Farnborough the most popular amongst our clients.”

It looks likely that full year numbers will meet and probably beat forecasts, given that the H1 EPS is already slightly more than 50% of the full year consensus with a strong H2 to come. And the dividend is also ahead of consensus forecasts, pointing to a 6.6p total divi compared to 6.29p forecasts: Http://www.investegate.co.uk/watkin-jones-plc--wjg-/rns/half-year-report/201706010700067768G/ I particularly liked this from the outlook: "Outlook The Group's student accommodation development business continues to be underpinned by the attractive fundamentals of the student accommodation market, with the Group continuing to see strong demand from UK and international clients. We have seen increased institutional demand for good quality purpose built assets, with a number of new international funds recently entering the market. This has had a positive effect on development values as competition has increased and yields have sharpened. Clients looking for scale see partnering with Watkin Jones as the best way to secure new assets in prime locations. "

Great to see some press attention here - unusually for such a tiddler, GAN is the main tip in today's Tempus column in the Times: Https://www.thetimes.co.uk/edition/business/gan-s-gambling-software-looks-a-good-bet-5w70r36ql "Gan’s gambling software looks a good bet he US gambling market has historically been a place where few British companies have wished to tread, but one exception ploughing a potentially lucrative furrow is Gan. Full-year results yesterday from the London-based business-to-business supplier of online gaming software showed losses narrowing as revenues rose 30 per cent year-on-year to a little under £8 million. Make no mistake, this Aim-listed business remains a tiddler with a market capitalisation of just £20 million, but analysts at its new broker believe the share price could easily treble as investors get comfortable with its model. Gan’s Gamestack software, developed over 15 years, gives physical casinos an online presence, enabling them to go after a digital customer base previously denied to them. At present the company has signed 13 partnerships with major US casino groups out of a total of more than 900, highlighting the potential for growth. Regulators appear to be opening up the market and as the authorities liberalise, the opportunities for Gan will grow, with the company earning money from providing the software that bricks-and-mortar casinos need to get online, as well as taking as much as a 35 per cent share of net gaming revenues. In the first three months of the year, active player-days on Gan’s software platform went above 2.2 million compared with about 1.7 million in the third quarter of last year, while average revenue per daily active user has risen over the same period from $7 to $7.69. These figures point to 2017 being the break-even year for the company as the $50 million investment in its core software starts to come good. And all of this is without factoring in the biggest cash cow of them all, simulated gaming. Here Gan is providing the software for a fast-growing market that allows real-world customers of casinos to buy virtual chips that they can use to gamble online. US law being what it is, these tokens cannot be redeemed for real money, but are instead used to buy services such as food, drinks, hotel rooms and free slot machine bets, building customer loyalty. This is already a multibillion-dollar business and big growth is expected, with Gan well placed. Four years on from its IPO, it appears the time finally might have come to put a few chips behind Gan and its casino clients. My advice Buy Why The US gambling industry looks to be evolving in favour of its business model"

There we have it - new recent highs....hopefully this is just the start of a breakout back to 80p for starters.

Very encouraging to see a non-exec buying £21,800 of shares at 218p today (via his wife), and also transferring his own shares into his wife's name, presumably to mitigate any forthcoming gains tax-wise: Http://www.investegate.co.uk/gama-aviation-plc--gmaa-/rns/director-pdmr-shareholding/201705301534296019G/